Press releases

New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes

LONDON, September 9, 2024 (GLOBE NEWSWIRE)– Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for the treatment of microsatellite stable metastatic colorectal cancer (MSS mCRC). The analysis revealed that prioritized peptides, selected using Treos’ proprietary computational technology, were key in driving immune responses and clinical outcomes across the studies.

At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer

PolyPEPI1018 is the first cancer vaccine to demonstrate promising results when combined with a PD-(L)1 inhibitor in late-stage microsatellite stable colorectal cancer (MSS CRC), a form of cancer -representing 96% of all metastatic CRC – historically resistant to checkpoint inhibitor immunotherapy.

LONDON and BOSTON, June 3, 2024– Treos Bio Limited, a clinical-stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer (MSS mCRC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting

LONDON and BOSTON – May 8, 2024– Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.

Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LONDON, June 05, 2023 (GLOBE NEWSWIRE)– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced the presentation of final results of the Phase 1b OBERTO-201 study of the Company’s lead product candidate, PolyPEPI1018, in combination with the oral chemotherapy TAS-102, for the treatment of patients with late-stage microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer

LONDON, June 27, 2022 – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 301 Phase 2 trial of PolyPEPI1018, the Company’s lead product candidate, in combination with atezolizumab, Roche’s PD-L1 inhibitor, for the treatment of patients with late-stage microsatellite stable metastatic colorectal cancer (MSS mCRC).

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

LONDON, February 7, 2022 – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced that the first patient has been dosed in the OBERTO 201 Phase 1b trial of PolyPEPI1018, the Company’s lead product candidate, as an add-on to standard-of-care third-line chemotherapy (TAS-102) for the treatment of patients with late-stage microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Treos Bio Announces FDA Clearance of IND Application for PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer

OBERTO 201 Phase 1b trial expected to initiate 3Q 2021
U.S. Department of Defense (“DoD”) Congressionally Directed Medical Research Program will fund the trial, to be conducted in collaboration with Mayo Clinic

LONDON, August 18, 2021 – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PolyPEPI1018, the Company’s lead product candidate, as an add-on to third-line chemotherapy (TAS-102) for the treatment of patients with late-stage metastatic colorectal cancer (mCRC).

Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor

Company expects to initiate a Phase I/II trial in Q4 2021

LONDON, July 7, 2021 – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide cancer immunotherapies, today announced a clinical collaboration with Roche in which Treos will evaluate the combination of PolyPEPI1018, its lead product candidate, and atezolizumab, Roche’s PD-L1-inhibitor, in patients with late stage microsatellite stable metastatic colorectal cancer (MSS mCRC). A Phase I/II trial evaluating PolyPEPI1018 in combination with atezolizumab is expected to begin in Q4 2021.

Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection

Results have strong implications for the development of global, highly immunogenic and long-lasting T cell-focused vaccines against various pathogens and diseases

LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects” in Frontiers in Genetics. The paper reviewed the potential of PolyPEPI-SCoV-2, the Company’s peptide vaccine candidate, to potentially address all four structural proteins of the COVID-19 virus in order to generate long-term immunity in virtually all human subjects, independent of ethnicity.

Treos Bio Announces the Appointment of Ruti Alon to its Board of Directors

LONDON, June 01, 2021 (GLOBE NEWSWIRE)– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the appointment of Ruti Alon to its Board of Directors. Ms. Alon joins Treos with over 40 years of executive and entrepreneurial expertise as a life sciences investor, mentor and leader for private and public biotechnology companies.

Treos Bio Announces $14 Million Convertible Loan Note Financing to Advance Platform of Computationally Designed Peptide-Based Cancer Immunotherapies

Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer

Financing was led by Luminous Ventures and the UK Government’s Future Fund

Isabel Fox, Co-Managing Partner at Luminous Ventures, joins Treos’ Board of Directors

LONDON, 31 March 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced that it closed a $14 million convertible loan note financing. The financing was led by Luminous Ventures and the UK Government’s Future Fund, both first-time investors in Treos. In addition, Isabel Fox, Co-Managing Partner of Luminous Ventures, joined Treos’ Board of Directors.

PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response

LONDON, Oct. 19, 2020 (GLOBE NEWSWIRE) — PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, today announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine. The study was published on the preprint service bioRxiv website at https://www.biorxiv.org/content/10.1101/2020.10.16.339937v1 and has been submitted for publication in a peer-reviewed journal.

Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine

LONDON, June 15, 2020 (GLOBE NEWSWIRE) — Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, today said that it has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.

Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation

LONDON, May 29, 2020 (GLOBE NEWSWIRE) — Treos Bio Limited, a clinical stage biopharma company developing precision peptide cancer immunotherapies, today presented positive final data from a Phase I/II study of PolyPEPI1018, its off-the-shelf multi-peptide treatment, in microsatellite stable metastatic colorectal cancer (MSS mCRC) patients during an online poster presentation released today at the 2020 ASCO Annual Meeting.

Treos Bio Presents Positive Data on Its Off-the-Shelf Shared Antigen-Based Cancer Vaccine Against Microsatellite-Stable Metastatic Colorectal Cancer and Personalized Vaccines Against Three Metastatic Cancers

The company presents two scientific posters on its proprietary platform technology at the Society for Immunotherapy of Cancer’s 34th annual meeting (SITC 2019) in National Harbor, Md.

LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) — Treos Bio has developed a unique approach to create cancer vaccines by focusing not just on the vaccine targets but also on delivering antigen targets to which each patient’s immune system can specifically respond. Its proprietary class-leading platform, the Personal Antigen Selection Calculator (PASCal), addresses both patient and tumor heterogeneity. PAScal enabled the development of two families of effective shared antigen-based cancer vaccines (“off-the-shelf” and “personalized”) that target 19 cancer indications and are commercially scalable, without need for tumor biopsy and on-demand manufacturing….

Treos Bio Reports Updated Positive Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer

The company presents four scientific posters on its proprietary platform technology at the 2019 ESMO Annual Congress

LONDON, Sept. 26, 2019 (GLOBE NEWSWIRE) — Treos Bio Limited, which is developing personal cancer vaccines combined with companion diagnostic devices, reported updated positive results on the second part of its phase 1/2 study (OBERTO) with the PolyPEPI1018 cancer vaccine as an add-on to maintenance therapy in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)…

Treos Bio Announces Positive Interim Results from a Phase 1/2 Clinical Trial of Precision Cancer Vaccine Plus Maintenance Therapy in Patients with Metastatic Colorectal Cancer

Study will be presented in poster session at the 2019 ASCO Annual Meeting

LONDON, 28 May 2019 – Treos Bio Limited, an immuno-oncology company developing next-generation, precision cancer vaccines combined with companion diagnostic devices, reported positive interim results from its first-in-man Phase 1/2 study of its precision cancer vaccine with maintenance therapy in patients with metastatic colorectal cancer (mCRC)..

Investigators Dose First Patient in Phase 1 Study of Treos Bio’s PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer

SAN FRANCISCO and LONDON, May 14, 2018—Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said investigators dosed the first patient in its Phase 1 trial of PolyPEPI™ 1018, the company’s investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).

Treos Bio Announces Activation of U.S. Clinical Trial Site for Phase 1 Study of PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal Cancer

SAN FRANCISCO and LONDON, April 11, 2018 (GLOBE NEWSWIRE) — Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said it had successfully activated its clinical trial site at the Mayo Clinic in Rochester, Minnesota for its Phase 1 trial of PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).

Treos Bio Names Gábor Illés as Its Chief Financial Officer

SAN FRANCISCO and LONDON, April 03, 2018 — Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today named Gábor Illés as its Chief Financial Officer. Mr. Illés has served as a non-executive investor director of Treos since the company’s inception.

Treos Bio Announces FDA Approval of IND of Its First PolyPEPI™ Precision Cancer Vaccine for Metastatic Colorectal Cancer

SAN FRANCISCO and LONDON, Jan. 24, 2018 — Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) Application for PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC), and has provided authorization to proceed with the Phase 1 study in mCRC patients.

Treos Bio Enters into Agreement with PPD to Manage First-in-Man Trial of Its Lead Therapeutic Cancer Vaccine Program

SAN FRANCISCO AND LONDON—September 20, 2017—Treos Bio Limited, which is developing precision peptide cancer vaccines coupled with companion diagnostics, today announced it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization. As part of the agreement, PPD^® Biotech, a PPD service dedicated to biotech and small to mid-sized pharmaceutical companies, will manage Treos Bio’s first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. This study will be conducted in the United States and Europe.

Treos Bio Raises $8 Million in Private Investment Round

Funding will carry company through early-stage clinical trial of its precision vaccine for colorectal cancer

SAN FRANCISCO, CA and LONDON, UNITED KINGDOM–(Marketwired – Feb 13, 2017) – Treos Bio, Ltd., which is developing precision cancer immunotherapies paired to companion diagnostics, today announced it completed an $8 million funding through a group of private investors…